Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Rembrandt 3-in-1 Targets Wider Consumer Base With Lower Price Point

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Rembrandt 3-in-1, a combination product comprising a whitening toothpaste, bleaching gel and whitening rinse, is positioned to attract a wider consumer audience than other Rembrandt items due to its lower price point, Den-Mat said.

You may also be interested in...



Rembrandt Powers Into New Toothpaste Category With Electric Brush Formula

Den-Mat's Rembrandt Power Brush Whitening Gel aims to fill a gap in the toothpaste category as the first premium whitening formula designed to be used with an electric toothbrush, the company said

Rembrandt Powers Into New Toothpaste Category With Electric Brush Formula

Den-Mat's Rembrandt Power Brush Whitening Gel aims to fill a gap in the toothpaste category as the first premium whitening formula designed to be used with an electric toothbrush, the company said

Rembrandt Powers Into New Toothpaste Category With Electric Brush Formula

Den-Mat's Rembrandt Power Brush Whitening Gel aims to fill a gap in the toothpaste category as the first premium whitening formula designed to be used with an electric toothbrush, the company said

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS093121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By